Elsevier

The Lancet

Volume 386, Issue 9993, 8–14 August 2015, Pages 512-514
The Lancet

Comment
Do we need more psoriasis therapies?

https://doi.org/10.1016/S0140-6736(15)60205-7Get rights and content

First page preview

First page preview
Click to open first page preview

References (13)

There are more references available in the full text version of this article.

Cited by (2)

  • Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    2018, The Lancet
    Citation Excerpt :

    Patients with psoriasis are at increased risk of developing several comorbidities, including cardiovascular disease, depression, metabolic syndrome, joint and entheseal disease, and inflammatory bowel disease.7,8 Although the introduction of biologics has improved treatment outcomes, an unmet need remains for therapies that provide predictable and durable skin clearance with convenient dosing, thereby improving patients' quality of life.9–12 Interleukin-23, a key regulator of multiple effector cytokines, has a pivotal role in the pathogenesis of psoriasis.13–16

View full text